Obesity — a global epidemic

APPROVED PRODUCTS

Qsymia (phentermine and topiramate extended-release capsules) is approved for use in the U.S. for weight management in adult and pediatric patients. Visit the Qsymia product page and review the Full Prescribing Information.

ABOUT OBESITY

Overweight and obesity result from an imbalance of energy intake (diet) and energy expenditure (physical activity). The World Health Organization (WHO) recognises obesity is a serious, complex chronic disease.

1 in 8

The WHO estimates that 1 in 8 people in the world are living with obesity.¹

Since 1990 rates of adult obesity worldwide have more than doubled, and adolescent obesity has quadrupled.¹

50%

It is estimated that by 2030, 50% of adults will be living with a high BMI (body mass index) and in the same year, 17% of men and 22% of women will be living with obesity.²

The impact of excess weight and obesity

In addition to biological factors, many aspects of a person's general well-being, environment and lifestyle can also cause weight gain. The impact and health risks caused by overweight and obesity are increasingly well documented and understood. Losing weight may improve some conditions that are associated with obesity.³

Heart Disease

Prediabetes and Type 2 Diabetes

Infertility

Some Cancers

Osteoarthritis

Nonalcoholic Fatty Liver Disease

Pulmonary disease (Sleep Apnea)

Neurodegenerative Diseases

High Blood Pressure

The World Obesity Federation estimates that obesity contributes to almost 4 million deaths annually globally, driving 43% of diabetes cases, up to 78% of hypertension, and over 13 types of cancer.⁴

SELECT FROM THE FOLLOWING:

CLINICAL KNOWLEDGE BASE

Weight management with Phentermine/ Topiramate MR

Phentermine/Topiramate MR has been extensively studied for weight management. This knowledge base provides access to various studies and journal articles.

VISIT KNOWLEDGE BASE

REFERENCES